Ventas, Inc. (VTR) Stock Price & How to Invest

Ventas, Inc. is an S&P 500 healthcare real estate investment trust that owns roughly 1,400 properties across North America and the United Kingdom, spanning senior housing communities, outpatient medical buildings, and research and lab (life science) assets. Its defining shift has been toward its senior housing operating portfolio (SHOP), which now accounts for more than half of net operating income and gives Ventas direct exposure to occupancy, rate, and margin trends rather than just fixed lease income. The company owns over 850 senior housing communities, and management has leaned hard into buying them, raising 2026 investment guidance to about $3 billion because acquiring communities has looked more attractive than building.

The investment picture blends REIT income with an unusually demographic-driven growth angle. Ventas has posted multiple consecutive years of double-digit same-store SHOP cash NOI growth (over 15% in Q1 2026), with expanding margins as an aging population meets constrained new senior housing supply. That growth has lifted normalized FFO per share and supported an 8% dividend increase for 2026, but it also comes with an operating-model that carries more earnings variability than a pure net-lease REIT, and the stock trades at a premium FFO multiple that assumes the growth continues.

As an operating (SHOP-heavy) REIT, Ventas carries more earnings variability than a pure net-lease landlord because occupancy, labor costs, and rate growth flow straight to NOI. A premium FFO multiple (roughly mid-20s price-to-FFO) leaves little room for disappointment if senior housing growth decelerates or supply eventually catches up. Interest rates matter twice: higher rates raise the cost of the debt REITs rely on and can pressure REIT valuations broadly. Large ongoing acquisitions carry integration and pricing risk, and any renewed pressure on senior housing occupancy (from a health event or weaker demand) would hit results directly. Life science and outpatient medical demand can also soften with tenant budgets.

22 analysts publish price targets on VTR, averaging $99.68 against a $93.51 price as of August 2026, or +6.6%. The published targets run from $86.00 to $114.00, a narrow spread, and the ratings split 18 buy, 5 hold, 0 sell. Over the last six months there have been 10 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full VTR forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Ventas, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Senior housing (SHOP) demographic tailwind. The 80-plus population is growing while new senior housing construction has stayed low, tightening supply just as demand rises. The most optimistic published target, $114.00, assumes this works close to its best case.

The case against. As an operating (SHOP-heavy) REIT, Ventas carries more earnings variability than a pure net-lease landlord because occupancy, labor costs, and rate growth flow straight to NOI. The most pessimistic target, $86.00, is roughly what VTR is worth if this bites instead.

Read the full bull and bear case on VTR, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Ventas, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$5.7B
• Q1 2026 revenue: ~$1.66B
• Normalized FFO/share (Q1 2026): ~$0.94
• 2026 FFO/share guidance: ~$3.82-$3.89
• Market cap: ~$47B
• Dividend yield: ~2.1%

VTR trades around $96 with a market cap near $47 billion, making it the second-largest healthcare REIT behind Welltower. At roughly a mid-20s price-to-FFO multiple, the market is paying up for a fifth consecutive year of double-digit senior housing NOI growth. The dividend yield is modest for a REIT at about 2.1%, reflecting both the growth premium and a payout that management has been rebuilding since the pandemic.

If you want VTR exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

Other names that sit close to VTR: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get VTR exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (SCHH, XLRE, REET), which spreads the position across many companies. Or build it into a focused thematic portfolio, so VTR sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where VTR fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

VTR is a demographically-driven healthcare REIT where the pace of senior housing NOI growth, and how much of it is already reflected in a premium FFO multiple, is the central question.

Whether VTR is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is VTR a buy or a sell?, and where the stock could go from here in the VTR stock forecast.

For income investors, whether VTR pays a dividend and how the payout looks is covered in does VTR pay a dividend? And to weigh VTR against a peer, read the full side-by-side comparisons: VTR vs WELL and VTR vs OHI.